Connect Biopharma announced it has regained compliance with the Nasdaq minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). The company received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC on July 16, 2025.
The confirmation stated that as of July 15, 2025, the company’s American Depositary Shares (ADSs) maintained a minimum closing bid price of at least $1.00 for a minimum of 10 consecutive business days. This resolves the deficiency notice received on March 24, 2025.
Accordingly, Connect Biopharma’s ADSs will continue to be listed and traded on Nasdaq, and the matter regarding the minimum bid price requirement is now closed. This ensures continued listing on the exchange and removes a significant regulatory overhang.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.